A Study to Evaluate the Pharmacokinetics of LY2624803 in Subjects With Hepatic Impairment
A Single Dose Pharmacokinetics Study of LY2624803 in Subjects With Hepatic Impairment
Sponsor: Eli Lilly and Company
Terminated
Trial was Terminated prior to subjects receiving study drug; no trial results
Other terminated trials from Eli Lilly and Company
A PHASE1 clinical study on Insomnia, this trial is terminated or withdrawn. The trial is conducted by Eli Lilly and Company and has accumulated 7 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Nov 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .